Related Experiment Video

Updated: Jun 23, 2026

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells
07:22

Isolation and Differentiation of Stromal Vascular Cells to Beige/Brite Cells

Published on: March 28, 2013

Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice

Mohan R Dasu1, Samuel Park, Sridevi Devaraj

  • 1Laboratory for Atherosclerosis and Metabolic Research, University of California, Davis, Medical Center, Sacramento, California 95817, USA. ravi.dasu@ucdmc.ucdavis.edu

Endocrinology
|April 25, 2009
PubMed

Insights

Pioglitazone (PIO) reduces inflammatory markers by decreasing Toll-like receptor 2 (TLR2) and Toll-like receptor 4 (TLR4) expression in human monocytes and mouse models. This study reveals a novel anti-inflammatory pathway for PIO.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Toll-like receptors (TLRs) are crucial innate immune sensors involved in inflammatory diseases.
  • Pioglitazone (PIO), a PPAR-gamma agonist, exhibits anti-inflammatory properties.

Purpose of the Study:

  • To investigate the anti-inflammatory effects of PIO on TLR2 and TLR4 expression.
  • To elucidate the impact of PIO on inflammatory signaling pathways.

Main Methods:

  • Human monocytes were treated with PIO and challenged with TLR2 (Pam3CSK4) and TLR4 (LPS) ligands.
  • Flow cytometry and real-time RT-PCR were used to assess TLR expression.
  • Experiments were also conducted in PIO-treated db/db mice.

Main Results:

  • PIO significantly decreased Pam3CSK4- and LPS-induced TLR2 and TLR4 expression in human monocytes.
  • PIO reduced inflammatory mediators including IL-1beta, IL-6, and TNF-alpha.
  • In vivo studies showed decreased TLR2 and TLR4 expression in PIO-treated mice.

Conclusions:

  • Pioglitazone inhibits TLR2 and TLR4 expression and associated inflammatory signaling.
  • PIO demonstrates a novel anti-inflammatory mechanism through TLR modulation.

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...